The Fox Chase Cancer Center (FCCC) and the University of Pennsylvania (PENN) Ovarian SPORE is submitted as a partnership between two Philadelphia NCI Cancer Centers requesting support for years 11 through 15 of this SPORE. Over the last 9 years the SPORE program has matured and evolved. Viewing the SPORE today, the notable difference in the new submission has been the recruitment of new and energetic leadership to the SPORE bringing new ideas, technologies, and institutional investment. This translational focus is a benefit of both the SPORE Program's maturity, the depth of research in ovarian cancer at the institutions, as well as nearly unique institutional resources that catalyzed the expansion of the ovarian cancer program at FCCC-PENN. Within the new SPORE are five highly translational Projects. The projects include: PI) Gene Methylation Signatures for Predictive Classification of Response to Therapy;P2) Improving the Estimation and Communication of Ovarian Cancer Risk among BRCA1/2 Carriers to Optimize Decision Making;P3) Therapeutic Micro RNA Strategies for Ovarian Cancer;P4) Targeting Signaling Networks via Novel RNAi Approaches to Improve Therapy for Ovarian Cancer;P5) Advancing T cell Therapy for Ovarian Cancer. The Programs are supported by three separate cores including an Administrative, Biospecimen and Tissue Procurement, and a Biostatistics and Bioinformatics Cores. The SPORE also has a highly effective Career Development Program and a Developmental Pilot Project Program which has been successful at launching the career of many junior investigators and has served to identify new Projects through the first ten years of the SPORE. The investment in the SPORE and the FCCC-PENN Ovarian Cancer Program between 2004 and 2014 comes through direct investments in the SPORE ($6.2 million), with another $10.9 million into the ovarian cancer programs and faculty at PENN and FCCC. In addition, the two NCI Cancer Centers have provided an additional $13.4 million in associated yet important investments supporting the gynecologic oncology clinical and research infrastructure. In addition, over 10 million dollars in collateral and follow on grants have been generated from FCCC-PENN Ovarian SPORE research in the last five years thus bringing the total ovarian cancer (but non-SPORE) investment into the ovarian cancer programs and infrastructure to over 41 million dollars.

Public Health Relevance

The current SPORE focuses on three key topics including the role of epigenetics in ovarian cancer, the discovery and validation of predictive biomarkers, and the development of targeted therapeutics in the treatment of ovarian cancer. The Projects are all translational and centered around a planned clinical trial either in women with ovarian cancer or alternatively in a population of women at high risk for developing ovarian cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Arnold, Julia T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fox Chase Cancer Center
United States
Zip Code
Xiao, Xue; Yang, Gong; Bai, Peng et al. (2016) Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway. BMC Cancer 16:582
Prudnikova, T Y; Villamar-Cruz, O; Rawat, S J et al. (2016) Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells. Oncogene 35:2178-85
Tan, Yinfei; Xin, Xiaoban; Coffey, Francis J et al. (2016) Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol 231:1142-50
Wang, Yifan; Bernhardy, Andrea J; Cruz, Cristina et al. (2016) The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res 76:2778-90
Zhang, Youyou; Feng, Yi; Hu, Zhongyi et al. (2016) Characterization of Long Noncoding RNA-Associated Proteins by RNA-Immunoprecipitation. Methods Mol Biol 1402:19-26
Hu, Xiaowen; Feng, Yi; Hu, Zhongyi et al. (2016) Detection of Long Noncoding RNA Expression by Nonradioactive Northern Blots. Methods Mol Biol 1402:177-88
Zhang, Youyou; He, Qun; Hu, Zhongyi et al. (2016) Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nat Struct Mol Biol 23:522-30
Beck, Tim N; Korobeynikov, Vladislav A; Kudinov, Alexander E et al. (2016) Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer. Cell Rep 16:657-71
Zhang, Shiwu; Mercado-Uribe, Imelda; Sood, Anil et al. (2016) Coevolution of neoplastic epithelial cells and multilineage stroma via polyploid giant cells during immortalization and transformation of mullerian epithelial cells. Genes Cancer 7:60-72
Daly, Mary B; Dresher, Charles W; Yates, Melinda S et al. (2015) Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res (Phila) 8:342-8

Showing the most recent 10 out of 303 publications